CytoDyn launches mid-stage study of leronlimab in nonalcoholic fatty liver disease

 

• The first patient has been enrolled in a Phase 2 clinical trial evaluating CytoDyn' (OTCQB:CYDY) leronlimab, for the treatment of non-alcoholic steatohepatitis (NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD).
• As previously reported, the Company’s preclinical study demonstrated strong positive data highlighting the potential of leronlimab in treating nonalcoholic fatty liver disease (NAFLD), a common precursor to NASH. Inhibition of CCR5 has been shown to be effective in reducing fibrosis in animal models of NASH liver fibrosis.
• Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.
• https://seekingalpha.com/news/3640733-cytodyn-launches-mid-stage-study-of-leronlimab-in-nonalcoholic-fatty-liver-disease